A phenylfuran-tetrahydroisoquinoline compound and its preparation and application

By designing and synthesizing phenylfuran-tetrahydroisoquinoline compounds, the shortcomings of existing P-gp inhibitors in clinical applications have been solved, significantly reversed multidrug-resistant tumor cells, and improved the sensitivity of chemotherapy drugs and Treatment effect.

CN115626918BActive Publication Date: 2024-11-05ZHEJIANG UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202211389431.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-08
Publication Date
2024-11-05
Estimated Expiration
2042-11-08

AI Technical Summary

Technical Problem

The existing P-gp inhibitors have poor selectivity, insufficient inhibitory activity, high toxicity and pharmacokinetic effects in clinical applications, resulting in increased toxic and side effects of chemotherapy drugs, making it difficult to effectively reverse multidrug-resistant tumor cells.

Method used

A series of phenylfuran-tetrahydroisoquinoline compounds were designed and synthesized. The compound was prepared by specific synthetic methods to inhibit P-gp, thereby increasing the accumulation of chemotherapy drugs in cells and tumor cells to chemotherapy drugs. Sensitivity.

Benefits of technology

This compound significantly reverses multidrug-resistant tumor cells, improves the sensitivity to the anti-tumor drug doxorubicin hydrochloride, and has simple preparation method, high yield, good biological activity, reduces cytotoxicity, and enhances the therapeutic effect of chemotherapy. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115626918B_ABST
    Figure CN115626918B_ABST
Patent Text Reader

Abstract

The present invention discloses a phenylfuran-tetrahydroisoquinoline compound and a preparation method and application thereof. The general structural formula of the compound is shown in Formula I and Formula II. The preparation method of the compound is simple and has a high yield. At the same time, the compound has good biological activity, can be used as a P-gp inhibitor or a tumor multidrug resistance reversal agent and a tumor metastasis inhibitor or a biological probe with good biological tolerance, and can be used clinically as a malignant tumor multidrug resistance reversal agent and a chemotherapy drug sensitizer, expanding the application prospects of benzofuran and tetrahydroisoquinoline structures in tumor multidrug resistance reversal agents. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

(I) Technical field

[0001] The invention belongs to the field of pharmaceutical chemical synthesis and drug therapy, and particularly relates to a phenylfuran-tetrahydroisoquinoline compound and a preparation method and application thereof. (II) Background technology

[0002] As the course of chemotherapy increases, the multidrug resistance (MDR) exhibited by tumors has long troubled clinicians and directly threatened the majority of patients (Curr Med Chem. 2012, 19, 1946-2025.). Among them, the overexpression of P-glycoprotein (P-gp) in the ATP-binding (ABC) transporter family on the surface of tumor cell membranes is the most widely studied mechanism of tumor MDR production (Eur J Med Chem. 2016, 118, 219-229.). As a common transmembrane protein, P-gp will be overexpressed on the cell membrane of tumor cells as chemotherapy proceeds, which is the biggest obstacle to the sustained effectiveness of chemotherapy. Studies have shown that inhibiting P-gp can increase the accumulation of chemotherapy drugs in cells, increase the sensitivity of resistant cells to chemotherapy drugs, exert the effects of chemotherapy drugs or induce tumor cell apoptosis, and then reverse MDR. Therefore, finding and studying drugs that inhibit P-gp has become one of the research hotspots in the field of overcoming the MDR of malignant tumors, and it is also a difficult problem that needs to be solved urgently in the clinic and the market.

[0003] The research and development of P-gp inhibitors has gone through three stages after decades of efforts. There are also drug molecules that have entered the clinical trial stage in the first three generations of inhibitors, but the main problems they face in clinical applications are: 1. The inhibitors have poor selectivity for P-gp; 2. The inhibitors have insufficient inhibitory activity on P-gp; 3. The toxicity of the inhibitor small molecules themselves cannot be ignored; 4. The inhibitors affect the pharmacokinetic properties of chemotherapy drugs and increase the toxic side effects of drugs (J.Med.Chem.2018,61,5108-5121). In order to obtain P-gp inhibitors with stronger anti-MDR activity, the present invention designs and synthesizes a series of phenylfuran-tetrahydroisoquinoline compounds. The results of biological activity tests show that this type of compound has a significant reversal of the MDR effect of multidrug-resistant tumor cells and increases the sensitivity of cells to the anti-tumor drug doxorubicin hydrochloride. (III) Summary of the invention

[0004] The purpose of the present invention is to provide a phenylfuran-tetrahydroisoquinoline compound and a preparation method and application thereof. The compound has good biological activity and can be used for the development and utilization of drugs for treating multidrug resistance of malignant tumor cells caused by multidrug resistance-related proteins, reversing the MDR effect of multidrug resistant tumor cells, and increasing the sensitivity of cells to the anti-tumor drug doxorubicin hydrochloride.

[0005] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0006] The present invention provides a phenylfuran-tetrahydroisoquinoline compound represented by formula (I) or formula (II),

[0007]

[0008]

[0009] In formula (I), R 1 is methyl, ethyl, isopropyl, butyl, isobutyl, pentyl, 1-cyclopropyl, 1-cyclobutyl, 1-cyclopentyl, 1-cinnamyl, 1-crotonyl, 2-indolyl, 3-indolyl, 4-indolyl, 2-benzofuranyl, 2-benzothienyl, 3-benzothienyl, 1-naphthyl, 2-naphthyl, 1-naphthyl; preferably, R 1 The base is 2-indolyl;

[0010] In formula (II), R 2 is one or more substitutions, said R 2 The radical is methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, methyl, ethyl, propyl, nitro, cyano or the like.

[0011] Preferably, the R 2 The radical is 4-methoxy, 5-methoxy, 6-methoxy, 7-methoxy, 4-methyl, 5-methyl, 6-methyl, 7-methyl, 4-fluoro, 5-fluoro, 6-fluoro, 7-fluoro, 4-chloro, 5-chloro, 6-chloro, 7-chloro, 4-bromo, 5-bromo, 6-bromo, 7-bromo, 5-nitro, 4-trifluoromethyl, 5-trifluoromethyl, 6-trifluoromethyl, 4,6-difluoro or 7-trifluoromethyl, most preferably 5-fluoro.

[0012] The present invention also provides a method for preparing the phenylfuran-tetrahydroisoquinoline compound, which comprises the following steps:

[0013] S1. In the presence of a diluent, the compound represented by formula (III) is reacted with oxalyl chloride (SOCl2) at 0-30°C for 0.5-5h to prepare a compound represented by formula (IV);

[0014] S2. In the presence of a diluent and an acid binding agent, the compound represented by formula (Ⅳ) is reacted with 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride at 0-160° C., and separated and purified to obtain an intermediate represented by formula (V);

[0015] S3. In the presence of a diluent, a base and a catalyst, the intermediate represented by formula (V) is reacted with 4-aminophenylboronic acid at 80 to 160° C., separated and purified to obtain an intermediate represented by formula (VI);

[0016] S4. In the presence of a diluent, a condensing agent and an acid binding agent, the intermediate represented by formula (VI) reacts with an organic acid represented by formula (VII) or formula (VIII) at 0 to 160° C., and separates and purifies to obtain a compound represented by formula (I) or formula (II);

[0017]

[0018]

[0019] In formula (VII), R 1 The radical is methyl, ethyl, isopropyl, butyl, isobutyl, pentyl, 1-cyclopropyl, 1-cyclobutyl, 1-cyclopentyl, 1-cinnamyl, 1-crotonyl, 2-indolyl, 3-indolyl, 4-indolyl, 2-benzofuranyl, 2-benzothienyl, 3-benzothienyl, 1-naphthyl, 2-naphthyl, 1-naphthylmethyl; in formula (I), R 1 The same as R in formula (VII) 1 base;

[0020] In formula (VIII), R 2 The group is one or more, the R 2 The radical is methoxy, ethoxy, propoxy, butoxy, phenoxy, trifluoromethoxy, methylenedioxy, fluorine, chlorine, bromine, iodine, trifluoromethyl, methyl, ethyl, propyl, nitro, cyano, etc.; Formula (II) R 2 The same as R in formula (VIII) 2 base.

[0021] That is, the following reaction occurs:

[0022]

[0023] In steps S1, S2, S3 and S4, the diluent is an inert organic solvent. The diluents in different steps may be the same or different. As a preferred embodiment, the diluent is selected from one of the following: benzene, toluene, xylene, chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, ether, diisopropyl ether, dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, acetone, butanone, methyl isobutyl ketone, acetonitrile, propionitrile, butyronitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-formanilide, N-methylpyrrolidone, hexamethylphosphoric triamide, methyl acetate, ethyl acetate, dimethyl sulfoxide, methanol, ethanol, n-propanol, isopropanol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether or diethylene glycol monoethyl ether. More preferably, the diluent is dichloromethane, benzene, toluene or tetrahydrofuran.

[0024] In steps S2 and S4, the presence of an acid binding agent is conducive to the reaction. The acid binding agent is preferably one of sodium hydroxide, potassium carbonate, sodium ethoxide, triethylamine, trimethylamine, tributylamine, pyridine, N,N-dimethylaniline, N,N-dimethylbenzylamine, N-methylpiperidine, N-methylmorpholine, N,N-dimethylaminopyridine, diazabicyclooctane, diazabicyclononene or diazabicycloundecene, more preferably sodium hydroxide or triethylamine.

[0025] The presence of the base in step S3 is conducive to the reaction, and the base is an organic base or an inorganic base, preferably one of sodium hydroxide, potassium carbonate, sodium carbonate, sodium methoxide, sodium ethoxide, trimethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylbenzylamine, N-methylpiperidine, N-methylmorpholine, N,N-dimethylaminopyridine, diazabicyclooctane, diazabicyclononene or diazabicycloundecene, more preferably potassium carbonate.

[0026] In step S3, the presence of the catalyst is conducive to the reaction. The catalyst is a zero-valent or divalent metal palladium catalyst, such as Pd(OAc)2, PdCl2, Pd(MeCN)2Cl2, Pd(PPh3)4, Pd(TFA)2, etc. More preferably, the catalyst is tetrakis(triphenylphosphine)palladium, i.e. Pd(PPh3)4.

[0027] In step S4, the presence of the condensing agent is conducive to the reaction. Preferably, the condensing agent is dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), 1-hydroxybenzotriazole (HOBt), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazole-tetramethyluronium hexafluorophosphate A mixture of one or more of phosphate ester (HBTU), O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), triphenylphosphine-polyhalomethane, triphenylphosphine-hexachloroacetone, triphenylphosphine-NBS or 3-acyl-2-thiothiazoline, more preferably a mixture of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) and 1-hydroxybenzotriazole (HOBt) in a substance amount ratio of 1:1.

[0028] Preferably, the reaction conditions of step S1 are 25-30°C for 0.5-5h, preferably 1.5-2h; the ratio of the amount of the compound represented by formula (III) to the diluent feed material is 1:25-80, preferably 1:55-60; the ratio of the amount of the compound represented by formula (III) to the SOCl2 feed material is 1:0.5-3, preferably 1:1.5.

[0029] Preferably, step S1 is carried out as follows: in a three-necked flask equipped with a thermometer, 2-carboxy-5-bromofuran represented by formula (III) and a diluent are added, the temperature is cooled to 0°C by stirring, oxalyl chloride is added dropwise, and the dropping speed is controlled to keep the temperature at about 0°C; after the dropwise addition is completed, the temperature is stirred for 30 minutes, and the system temperature is maintained at 0°C; the temperature is slowly raised to room temperature, reacted at 25°C for 1.5 hours, and the solvent is evaporated to obtain a light yellow solid, which is the compound represented by formula (IV); the diluent is dichloromethane.

[0030] Preferably, in step S2, the reaction temperature of the compound represented by formula (IV) and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride can be carried out in a wide range according to the selection of the diluent, preferably 0-160°C, and the reaction time is 3-15 hours; more preferably 25-30°C for 9.5-10 hours. The ratio of the amount of the compound represented by formula (IV) to the diluent feed material is 1:25-80, preferably 1:55-60; the ratio of the amount of the compound represented by formula (IV) to the feed material of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride is 1:0.5-5, preferably 1:1; the ratio of the amount of the compound represented by formula (IV) to the feed material of the acid binding agent is 1:0.5-5, preferably 1:3.

[0031] Preferably, step S2 is performed as follows: add 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride and diluent a to a three-necked flask equipped with a thermometer, stir and cool to 0°C, drip 10% acid-binding agent a aqueous solution, and control the dripping speed to keep the temperature at about 0°C; after the dripping is completed, stir for 30 minutes, maintain the system temperature at 0°C, and simultaneously drip diluent b solution represented by formula (IV) and 10% (wt.) acid-binding agent b aqueous solution, and control the dripping speed to add both at the same time; after the dripping is completed, slowly warm to room temperature, react at 25°C for 9.5 to 10 hours, filter with filter paper, collect the organic phase, dry with anhydrous magnesium sulfate overnight, filter out the desiccant and evaporate the solvent to obtain a light yellow solid; after the obtained light yellow solid is dissolved with ethyl acetate, load on a silica gel column ( Silica gel 200-300 mesh, column height 10 cm, inner diameter 2 cm), using petroleum ether: ethyl acetate in a volume ratio of 1:1 as eluent, eluting for 3 column volumes, using petroleum ether: ethyl acetate in a volume ratio of 1:1 as a developing solvent for thin layer chromatography monitoring, collecting the effluent with an Rf of 0.3, and distilling off the solvent to obtain the intermediate represented by formula (V); the diluent a and the diluent b are the same diluents, the letters themselves have no meaning, the amount of the diluent is calculated based on the total amount of the diluent a and the diluent b, and the diluent a or the diluent b are preferably dichloromethane; the acid binder a aqueous solution is the same as the acid binder in the acid binder b aqueous solution, the letters themselves have no meaning, the amount of the acid binder is calculated based on the total amount of the acid binder in the acid binder a aqueous solution and the acid binder b aqueous solution, and the acid binder a and the acid binder b are preferably sodium hydroxide.

[0032] Preferably, in step S3, the reaction temperature of the intermediate represented by formula (V) and 4-aminophenylboronic acid can be carried out in a wide range according to the selection of the diluent, preferably 80-160°C for 8-20 hours, more preferably 85-100°C for 12 hours. The ratio of the amount of the compound represented by formula (V) to the base feed material is 1:1-5, preferably 1:3; the ratio of the amount of the compound represented by formula (V) to the catalyst feed material is 1:0.001-0.1, preferably 1:0.004; the ratio of the amount of the compound represented by formula (V) to the feed material of 4-aminophenylboronic acid is 10.5-5, preferably 1:1; the ratio of the amount of the compound represented by formula (V) to the diluent feed material is 1:25-80, preferably 1:35-40.

[0033] Preferably, step S3 is carried out as follows: in a three-necked flask equipped with a thermometer, under nitrogen protection, 4-aminophenylboronic acid, a catalyst, a base, and a compound represented by formula (V) and a diluent are added in sequence, and the mixture is reacted at 85° C. for 12 hours; filtered, the organic layer is washed with water and then dried with magnesium sulfate overnight; the solvent is evaporated after filtering out the desiccant to obtain a white solid; the white solid is dissolved in ethyl acetate, and then loaded onto a silica gel column (silica gel 200-300 mesh, column height 10 cm, inner diameter 2 cm), and eluted with petroleum ether:ethyl acetate in a volume ratio of 1:1, eluted for 3 column volumes, and monitored by thin layer chromatography with petroleum ether:ethyl acetate in a volume ratio of 1:1 as a developing solvent, and the effluent with an Rf of 0.2 is collected, and the solvent is evaporated to obtain a compound represented by formula (VI); the catalyst is tetrakis(triphenylphosphine)palladium; the base is potassium carbonate, and the diluent is toluene.

[0034] Preferably, in step S4, the reaction temperature of the compound represented by formula (VI) and the organic acid can be carried out in a wide range according to the selection of the diluent, preferably 0-160°C for 12-24 hours, more preferably 25-30°C for 18 hours. The ratio of the amount of the compound represented by formula (VI) to the organic acid feed material represented by formula (VII) or formula (VIII) is 1:0.5-1.5, preferably 1:1; the ratio of the amount of the compound represented by formula (VI) to the condensing agent feed material is 1:0.5-1.5, preferably 1:1; the ratio of the amount of the compound represented by formula (VI) to the acid binding agent feed material is 1:1-5, preferably 1:2; the ratio of the amount of the compound represented by formula (VI) to the diluent feed material is 1:25-80, preferably 1:35-40.

[0035] Preferably, step S4 is carried out as follows: in a three-necked flask equipped with a thermometer, an organic acid represented by formula (VII) or formula (VIII), a condensing agent, an acid binding agent, a compound represented by formula (VI) and a diluent are added in sequence, reacted at 25° C. for 18 h, filtered, the organic layer is washed with water and dried over magnesium sulfate overnight, the desiccant is filtered out and the solvent is evaporated to obtain a white solid, the white solid is dissolved in ethyl acetate, and loaded onto a silica gel column (silica gel 200-300 mesh, column height 10 cm, inner diameter 2 cm), with a volume ratio of 3: The method comprises the following steps: the step of: using petroleum ether:ethyl acetate in a volume ratio of 1:1 as the eluent, eluting for 3 column volumes, performing thin layer chromatography monitoring with petroleum ether:ethyl acetate in a volume ratio of 2:1 as the developing solvent, collecting the effluent with an Rf of 0.5, and evaporating the solvent to obtain a compound represented by formula (I) or formula (II); the condensing agent is preferably a mixture of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) and 1-hydroxybenzotriazole (HOBt) in a molar ratio of 1:1; the diluent is toluene; and the acid binding agent is triethylamine.

[0036] All of the above intermediates or target compounds can be purified by conventional separation techniques such as recrystallization or chromatography.

[0037] The present invention also provides an application of a compound represented by formula (I) or formula (II) in the preparation of a P-gp inhibitor.

[0038] The inhibitor is a tumor multidrug resistance reversal agent or a tumor metastasis inhibitor. The inhibitor also includes a pharmaceutically acceptable salt.

[0039] The compound of the present invention can be used in combination with anti-tumor drugs (clinical chemotherapy drugs) such as alkylating agents (such as cyclophosphamide or cisplatin), antimetabolites (such as 5-fluorouracil or hydroxyurea), topoisomerase inhibitors (such as camptothecin or topotecan), cell microtubule inhibitors (such as paclitaxel or vinblastine), DNA intercalating agents (such as doxorubicin or daunorubicin) and lysine kinase inhibitors (such as gefitinib). Through combined treatment with anti-tumor drugs, the sensitivity of multidrug-resistant tumor cells to anti-tumor drugs is enhanced, thereby improving the chemotherapy treatment effect.

[0040] The preparation method of the compound of the present invention is simple and has a high yield. Experiments have shown that the compound has a significant sensitization effect on cancer cell lines that show drug resistance at a concentration that is not cytotoxic when used alone and in combination with anti-tumor drugs. As a preferred embodiment, the cancer cell line is a human breast cancer cell line resistant to doxorubicin (MCF-7 / ADR), and the compound I or II is used in combination with doxorubicin hydrochloride to effectively improve the efficacy of doxorubicin hydrochloride.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] The invention discloses a phenylfuran-tetrahydroisoquinoline compound and a preparation method and application thereof. The preparation method of the compound is simple and has high yield. The compound has good biological activity and can be used as a P-gp inhibitor or a tumor multidrug resistance reversal agent and a tumor metastasis inhibitor or a biological probe with good biological tolerance. It can be used clinically as a malignant tumor multidrug resistance reversal agent and a chemotherapy drug sensitizer, which expands the application prospects of benzofuran and tetrahydroisoquinoline structures in tumor multidrug resistance reversal agents. (IV) Description of the drawings

[0043] Figure 1 It is a hydrogen nuclear magnetic resonance spectrum, A represents the compound represented by formula (I-1), and B represents the compound represented by formula (II-1). (V) Specific implementation methods

[0044] The present invention is further explained below in conjunction with specific examples, but the specific examples do not limit the present invention in any way. Unless otherwise specified, the reagents and methods involved in the examples are all commonly used reagents and methods in the art.

[0045] The room temperature described in the present invention refers to 25-30°C.

[0046] Example 1: Preparation of N-(4-(5-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)furan-2-yl)phenyl)acetamide (I-1)

[0047]

[0048] S1. Add 2-carboxyl-5-bromofuran (7.5 mmol) and 30 ml of dichloromethane to a 50 ml three-necked flask equipped with a thermometer, stir and cool to 0°C, add 11.25 mmol of oxalyl chloride dropwise, control the dropping speed to keep the temperature at about 0°C, and stir for 30 minutes after the addition is complete. Slowly warm to room temperature and react at 25°C for 1.5 hours. After distilling off the solvent, 1.57 g of a light yellow solid is obtained, which is 5-bromo-2-furancarbonyl chloride shown in formula (IV).

[0049] S2. Add 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (7.5mmol) and 20ml dichloromethane to a 50ml three-necked flask equipped with a thermometer, stir and cool to 0℃, add 3ml of 10% (wt.) sodium hydroxide aqueous solution (containing 15mmol sodium hydroxide), and control the dropping speed to keep the temperature at about 0℃. Stir for 30min after the addition is completed. Maintain the system temperature at 0℃, and at the same time add 10ml of 0.75mmol / L dichloromethane solution of 5-bromo-2-furancarbonyl chloride shown in formula (Ⅳ) (containing 7.5mmol 5-bromo-2-furancarbonyl chloride) and 3ml of 10% (wt.) sodium hydroxide aqueous solution (containing 7.5mmol sodium hydroxide). Control the dropping speed so that both are added at the same time. After the addition is completed, slowly warm to room temperature and react at 25℃ for 9.5 to 10h. Filter with filter paper, collect the organic phase and dry it with anhydrous magnesium sulfate overnight. Filter out the desiccant and evaporate the solvent to obtain a light yellow solid. The obtained light yellow solid was dissolved with 0.2 ml of ethyl acetate and loaded on a silica gel column (silica gel 200-300 mesh, column height 10 cm, inner diameter 2 cm), with petroleum ether: ethyl acetate in a volume ratio of 1:1 as the eluent, eluted for 3 column volumes, and monitored by thin layer chromatography with petroleum ether: ethyl acetate in a volume ratio of 1:1 as the developing solvent, and collected the effluent with Rf of 0.3. After evaporating the solvent, 2.71 g of the intermediate shown in formula (V), namely 6-bromo-2-(2'-H-3,4-dihydro-6,7-methoxyisoquinoline)furan-2-carboxamide, was obtained for the next reaction.

[0050] S3. In a 50ml three-necked flask equipped with a thermometer, under nitrogen protection, add 6mmol 4-aminophenylboronic acid, 0.025mmol tetrakis(triphenylphosphine)palladium, 18mmol potassium carbonate and 6mmol intermediate represented by formula (V) and 25ml toluene in sequence, and react at 85℃ for 12h. Filter, wash the organic layer with water and dry it with magnesium sulfate overnight. Filter out the desiccant and evaporate the solvent to obtain a white solid. After the white solid is dissolved with 0.1ml of ethyl acetate, load it on a silica gel column (silica gel 200-300 mesh, column height 10cm, inner diameter 2cm), use petroleum ether: ethyl acetate in a volume ratio of 1:1 as the eluent, elute for 3 column volumes, use petroleum ether: ethyl acetate in a volume ratio of 1:1 as the developing solvent for thin layer chromatography monitoring, collect the effluent with Rf of 0.2, evaporate the solvent to obtain 2.19g of compound represented by formula (VI), which is used for the next reaction.

[0051] S4. In a 50 ml three-necked flask equipped with a thermometer, add 5 mmol of acetic acid represented by formula (VII-1), 2.5 mmol of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), 2.5 mmol of 1-hydroxybenzotriazole (HOBt), 10 mmol of triethylamine and 5 mmol of the compound represented by formula (VI) and 20 ml of toluene in sequence, and react at 25°C for 18 hours. Filter, wash the organic layer with water and dry it with magnesium sulfate overnight. Filter out the desiccant and evaporate the solvent to obtain a white solid. The white solid was dissolved with 0.2 ml of ethyl acetate and loaded onto a silica gel column (silica gel 200-300 mesh, column height 10 cm, inner diameter 2 cm), with petroleum ether:ethyl acetate in a volume ratio of 3:1 as the eluent, eluted for 3 column volumes, and monitored by thin layer chromatography with petroleum ether:ethyl acetate in a volume ratio of 2:1 as the developing solvent, and the effluent with Rf of 0.5 was collected. After the solvent was evaporated, 1.98 g of the compound represented by formula (I-1) was obtained, with a total yield of 85%. The physicochemical constants and high-resolution mass spectrometry data are shown in Table 1, the nuclear magnetic resonance hydrogen spectrum data are shown in Table 3, and the nuclear magnetic resonance hydrogen spectrum is shown in Figure 1 shown.

[0052] Under the same conditions, R1 of the compound represented by formula (VII) in step S4 is replaced by the substituents shown in Table 1 to obtain compounds represented by Ⅰ-2 to Ⅰ-20 in Table 1, respectively.

[0053] Under the same conditions, the compound represented by formula (VII) is replaced by the compound represented by formula (VIII) listed in Table 2 to obtain compounds represented by II-1 to II-11 in Table 2 respectively.

[0054] The appearance, yield and high-resolution mass spectrum data of the above compounds are listed in Table 1, and the results of H NMR spectrum are listed in Table 3. It can be seen from the above that the structures of the above compounds are correct and they are all compounds represented by Formula I and II.

[0055] Table 1 Physicochemical constants and high resolution mass spectrometry data of the compound represented by formula I

[0056]

[0057]

[0058] Table 2 Physicochemical constants and high resolution mass spectrometry data of the compounds represented by formula II

[0059]

[0060] Table 3 H NMR data of compounds represented by formula I and II

[0061]

[0062]

[0063]

[0064] Example 2: Cytotoxicity of phenylfuran-tetrahydroisoquinoline compounds represented by formula (I) and formula (II) against MCF-7 / ADR cells

[0065] Cell line: MCF-7 / ADR (human breast cancer cell line resistant to adriamycin, purchased from Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.).

[0066] Test compound: Each compound prepared in Example 1 was prepared into a 5 μM test compound solution using dimethyl sulfoxide (DMSO).

[0067] Positive control drugs: Cyclosporin A and Tariquidar were prepared into 5 μM positive control drug solutions using DMSO.

[0068] Test method: MTT (methyl thiazolyl tetrazolium) method was used to test the cell proliferation activity of the compounds.

[0069] MCF-7 / ADR cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum at 37°C and 5% CO2 saturated humidity until the logarithmic growth phase. Cells in the logarithmic growth phase were taken and suspended in RPMI 1640 medium containing 10% fetal bovine serum. 5 / mL density was inoculated in a 96-well culture plate, 100μL per well, divided into blank control group, test compound group, and positive control group. Different test compounds were added to the test compound group, and the final concentration was 5μmol / L; the blank control group was given an equal volume of PBS, and the positive control group was added to the positive control drug, and the final concentration was 5μmol / L. Cultured for 48 hours at 37°C and 5% CO2 saturated humidity, MTT working solution was added, centrifuged after 4h, the culture solution was poured off, 100μL of DMSO was added to each well to dissolve, and then the absorbance was read at a wavelength of 490nm on an ELISA reader to calculate the effect of the test compound on the survival rate of the cells.

[0070] Cell survival rate = (average OD value of experimental group / average OD value of control group) × 100%

[0071] The MTT method was used to determine the cytotoxic effects of the test compounds on MCF-7 / ADR cells, and the results are shown in Table 4. The data show that the compounds numbered I-15, I-16, and I-17 have relatively obvious cytotoxicity, which is comparable to the control drug Tariquidar, while the toxicity of other compounds is weaker, all lower than that of cyclosporine.

[0072] Table 4 Inhibition rate of compounds of formula I and II on MCF-7 / ADR cells at 5 μM test concentration

[0073]

[0074] Example 3: Study on the multidrug resistance reversal activity of phenylfuran-tetrahydroisoquinoline compounds represented by formula (I) and formula (II) on MCF-7 / ADR cells.

[0075] Cell line: MCF-7 / ADR (human breast cancer cell line resistant to adriamycin, purchased from Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.).

[0076] Test compound: Each compound prepared in Example 1 was prepared into a 5 μM test compound solution using dimethyl sulfoxide (DMSO).

[0077] Positive control drugs: Cyclosporin A and Tariquidar were prepared into 5 μM positive control drug solutions using DMSO.

[0078] Test method: MTT (methyl thiazolyl tetrazolium) method was used to test the cell proliferation activity of the compound combined with doxorubicin.

[0079] MCF-7 / ADR cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum at 37°C and 5% CO2 saturated humidity until the logarithmic growth phase. Cells in the logarithmic growth phase were taken and suspended in RPMI 1640 medium containing 10% fetal bovine serum. 5 / mL density was inoculated in a 96-well culture plate, 100μL per well, and divided into a blank control group, a test compound group, and a positive control group. The test compound group was added with doxorubicin at a final concentration of 0.001, 0.01, 0.1, 1, 10μM and different test compounds at a final concentration of 5μM; the positive control group was given doxorubicin at a final concentration of 0.001, 0.01, 0.1, 1, 10μM and different control drugs at a final concentration of 5μM; the blank control group was given an equal volume of PBS. Cultured for 48 hours at 37°C and 5% CO2 saturated humidity, MTT working solution was added, centrifuged after 4h, the culture solution was poured off, 100μL DMSO was added to each well to dissolve, and then the optical density was read at a wavelength of 490nm on an ELISA reader to calculate the effect of the compound on the survival rate of the cells. Calculate the antiproliferative activity IC of doxorubicin on MCF-7 / ADR cells when combined with 5μM of the compound represented by formula (Ⅰ) or formula (Ⅱ) 50 (μM) and multidrug resistance reversal fold (RF).

[0080] Table 5 Results of the multidrug resistance reversal activity of 5 μM compounds of formula Ⅰ and Ⅱ on MCF-7 / ADR cells

[0081]

[0082] a IC of doxorubicin combined with test compound (5 μM) 50 value. b Reversal fold = IC 50 (ADR) / IC 50 (P-gp inhibitor+ADR). c Doxorubicin alone IC 50 (ADR).

[0083] As can be seen from Table 5, the compounds represented by formula (I) and (II) generally have good activity in reversing multidrug resistance of tumor cells, and many of them exceed the activity of control drugs Cyclosporin A and Tariquidar. Among them, the compound represented by formula (II-4) combined with doxorubicin has the best anti-multidrug resistant tumor proliferation activity and has good application prospects.

Claims

1. A phenylfuran-tetrahydroisoquinoline compound represented by formula (I) or formula (II), In formula (I), R 1 is 1-cyclopropyl, 1-cyclobutyl, 1-cyclopentyl, 1-cinnamyl, 2-indolyl, 3-indolyl, 4-indolyl; In formula (II), R 2 is one or more substitutions, said R 2 The radical is methoxy, ethoxy, propoxy, butoxy, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, or nitro.

2. A method for preparing the phenylfuran-tetrahydroisoquinoline compound according to claim 1, characterized in that: The method comprises the following steps: S1. In the presence of a diluent, the compound represented by formula (III) reacts with oxalyl chloride at 0-30° C. for 0.5-5 h to prepare a compound represented by formula (IV); the diluent is an inert organic solvent; S2. In the presence of a diluent and an acid-binding agent, the compound represented by formula (IV) reacts with 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride at 0-160° C., and is separated and purified to obtain an intermediate represented by formula (V); the diluent is the same as step S1; the acid-binding agent is one of sodium hydroxide, potassium carbonate, sodium ethoxide, triethylamine, trimethylamine, tributylamine, pyridine, N,N-dimethylaniline, N,N-dimethylbenzylamine, N-methylpiperidine, N-methylmorpholine, N,N-dimethylaminopyridine, diazabicyclooctane, diazabicyclononene or diazabicycloundecene; S3. In the presence of a diluent, a base and a catalyst, the intermediate represented by formula (V) reacts with 4-aminophenylboronic acid at 80-160° C., and is separated and purified to obtain an intermediate represented by formula (VI); the diluent is the same as step S1; the base is one of sodium hydroxide, potassium carbonate, sodium carbonate, sodium methoxide, sodium ethoxide, trimethylamine, pyridine, N,N-dimethylaniline, N,N-dimethylbenzylamine, N-methylpiperidine, N-methylmorpholine, N,N-dimethylaminopyridine, diazabicyclooctane, diazabicyclononene or diazabicycloundecene; the catalyst is a zero-valent or divalent metal palladium catalyst; S4. In the presence of a diluent, a condensing agent and an acid-binding agent, the intermediate represented by formula (VI) reacts with an organic acid represented by formula (VII) or formula (VIII) at 0-160°C, and is separated and purified to obtain a compound represented by formula (I) or formula (II); the diluent is the same as step S1; the acid-binding agent is the same as step S2; the condensing agent is dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide A mixture of one or more of amine, 1-hydroxybenzotriazole, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, O-benzotriazole-tetramethyluronium hexafluorophosphate, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroboric acid, triphenylphosphine-polyhalomethane, triphenylphosphine-hexachloroacetone, triphenylphosphine-NBS or 3-acyl-2-thiothiazoline; In formula (VII), R 1 The radical is 1-cyclopropyl, 1-cyclobutyl, 1-cyclopentyl, 1-cinnamyl, 2-indolyl, 3-indolyl, 4-indolyl; in formula (I), R 1 The same as R in formula (VII) 1 base; In formula (VIII), R 2 The group is one or more, the R 2 The radical is methoxy, ethoxy, propoxy, butoxy, fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, or nitro; R 2 The same as R in formula (VIII) 2 base.

3. The preparation method according to claim 2, characterized in that: The diluent in step S1 is selected from one of the following: benzene, toluene, xylene, chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride, ether, diisopropyl ether, dioxane, tetrahydrofuran, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, acetone, butanone, methyl isobutyl ketone, acetonitrile, propionitrile, butyronitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-formanilide, N-methylpyrrolidone, hexamethylphosphoric triamide, methyl acetate, ethyl acetate, dimethyl sulfoxide, methanol, ethanol, n-propanol, isopropanol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether or diethylene glycol monoethyl ether.

4. The preparation method according to claim 2, characterized in that: Step S1 is carried out as follows: in a three-necked flask equipped with a thermometer, 2-carboxyl-5-bromofuran represented by formula (III) and a diluent are added, the temperature is cooled to 0°C with stirring, oxalyl chloride is added dropwise, and the dropping speed is controlled to keep the temperature at about 0°C; after the dropwise addition is completed, the temperature is stirred for 30 minutes, and the system temperature is maintained at 0°C; the temperature is slowly raised to room temperature, reacted at 25°C for 1.5 hours, and the solvent is evaporated to obtain a light yellow solid, which is the compound represented by formula (IV); the diluent is dichloromethane; the ratio of the amount of the compound represented by formula (III) to the diluent is 1:25-80; the ratio of the amount of the compound represented by formula (III) to the oxalyl chloride is 1:0.5-3.

5. The preparation method according to claim 2, characterized in that: Step S2 is carried out as follows: add 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride and diluent a to a three-necked flask equipped with a thermometer, stir and cool to 0°C, drip an acid-binding agent a aqueous solution with a mass concentration of 10%, and control the dripping speed to keep the temperature at about 0°C; after the dripping is completed, stir for 30 minutes, maintain the system temperature at 0°C, and simultaneously drip a diluent b solution represented by formula (IV) and an acid-binding agent b aqueous solution with a mass concentration of 10%, and control the dripping speed to add both at the same time; after the dripping is completed, slowly warm to room temperature, react at 25°C for 9.5 to 10 hours, filter with filter paper, collect the organic phase, dry with anhydrous magnesium sulfate overnight, filter out the desiccant and evaporate the solvent to obtain a light yellow solid; after the obtained light yellow solid is dissolved with ethyl acetate, load on a silica gel column, use petroleum ether:ethyl acetate in a volume ratio of 1:1 as eluent, and elute 3 The method comprises the following steps: a column volume, performing thin layer chromatography monitoring with petroleum ether:ethyl acetate in a volume ratio of 1:1 as a developing solvent, collecting an effluent with an Rf of 0.3, and distilling off the solvent to obtain an intermediate represented by formula (V); the diluent a and the diluent b are both dichloromethane, and the amount of the diluent is calculated based on the total amount of the diluent a and the diluent b; the acid binding agent in the acid binding agent a aqueous solution and the acid binding agent in the acid binding agent b aqueous solution are both sodium hydroxide, and the amount of the acid binding agent is calculated based on the total amount of the acid binding agent in the acid binding agent a aqueous solution and the acid binding agent b aqueous solution; the ratio of the amount of the compound represented by formula (IV) to the diluent feed material is 1:25-80; the ratio of the amount of the compound represented by formula (IV) to the feed material of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride is 1:0.5-5; the ratio of the amount of the compound represented by formula (IV) to the acid binding agent feed material is 1:0.5-5.

6. The preparation method according to claim 2, characterized in that: Step S3 is carried out as follows: in a three-necked flask equipped with a thermometer, under nitrogen protection, 4-aminophenylboronic acid, a catalyst, a base, a compound represented by formula (V) and a diluent are added in sequence, and the mixture is reacted at 85° C. for 12 hours; filtering, washing the organic layer with water and drying it with magnesium sulfate overnight; filtering out the desiccant and evaporating the solvent to obtain a white solid; dissolving the white solid with ethyl acetate, loading the sample onto a silica gel column, using petroleum ether:ethyl acetate in a volume ratio of 1:1 as an eluent, eluting for 3 column volumes, performing thin layer chromatography monitoring with petroleum ether:ethyl acetate in a volume ratio of 1:1 as a developing solvent, and collecting R The effluent with f being 0.2 is distilled off to obtain a compound represented by formula (VI); the catalyst is tetrakis(triphenylphosphine)palladium; the base is potassium carbonate, and the diluent is toluene; the ratio of the amount of the compound represented by formula (V) to the base feed material is 1:1-5; the ratio of the amount of the compound represented by formula (V) to the catalyst feed material is 1:0.001-0.1; the ratio of the amount of the compound represented by formula (V) to the 4-aminophenylboronic acid feed material is 10.5-5; the ratio of the amount of the compound represented by formula (V) to the diluent feed material is 1:25-80.

7. The preparation method according to claim 2, characterized in that: Step S4 is carried out as follows: in a three-necked flask equipped with a thermometer, an organic acid represented by formula (VII) or formula (VIII), a condensing agent, an acid binding agent, a compound represented by formula (VI) and a diluent are added in sequence, reacted at 25° C. for 18 hours, filtered, the organic layer is washed with water and dried over magnesium sulfate overnight, the desiccant is filtered out and the solvent is evaporated to obtain a white solid, the white solid is dissolved in ethyl acetate, loaded on a silica gel column, and eluted with petroleum ether:ethyl acetate in a volume ratio of 3:1, eluted for 3 column volumes, and monitored by thin layer chromatography with petroleum ether:ethyl acetate in a volume ratio of 2:1 as a developing solvent, and the effluent with an Rf of 0.5 is collected, and the solvent is evaporated to obtain a compound represented by formula (I) or formula The compound represented by formula (II) is as follows; the condensing agent is a mixture of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenzotriazole in a molar ratio of 1:1; the diluent is toluene; the acid binding agent is triethylamine; the molar ratio of the compound represented by formula (VI) to the organic acid represented by formula (VII) or formula (VIII) is 1:0.5-1.5; the molar ratio of the compound represented by formula (VI) to the condensing agent is 1:0.5-1.5; the molar ratio of the compound represented by formula (VI) to the acid binding agent is 1:1-5; the molar ratio of the compound represented by formula (VI) to the diluent is 1:25-80.

8. Use of the compound of formula (I) or (II) according to claim 1 in the preparation of a P-gp inhibitor.

9. The use according to claim 8, characterized in that The inhibitor is a tumor multidrug resistance reversal agent or a tumor metastasis inhibitor.

Citation Information

Patent Citations

  • Furan ring 2, 5-disubstituted-tetrahydroisoquinoline compound and preparation and application thereof

    CN112480091A

  • Thiophene 2, 5-disubstituted-tetrahydroisoquinoline compound and preparation and application thereof

    CN112480094A

  • Phenylfuran-2-tetrahydroisoquinoline compounds containing amido bonds as well as preparation method and application thereof

    CN112552290A

  • Compound library

    WO2022149617A1